 | • レポートコード：MRC23Q38888 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、89ページ • 納品方法：Eメール（2-3日） • 産業分類：医療機器 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のウイルス様粒子市場について調査・分析し、世界のウイルス様粒子市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（大腸菌、酵母、昆虫細胞、その他）、用途別セグメント分析（ワクチン、治療、バイオイメージング、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、The Native Antigen Company、Creative BioStructure、Creative Biolabs、Leadgene Biomedical、Abcam、ACROBiosystems、Gentarget、VectorBuilderなどが含まれています。 世界のウイルス様粒子市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ウイルス様粒子市場規模を推定する際に考慮しました。本レポートは、ウイルス様粒子の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ウイルス様粒子に関するビジネス上の意思決定に役立てることを目的としています。 ・ウイルス様粒子市場の概要 - 製品の定義 - ウイルス様粒子のタイプ別セグメント - 世界のウイルス様粒子市場規模：タイプ別分析（大腸菌、酵母、昆虫細胞、その他） - ウイルス様粒子の用途別セグメント - 世界のウイルス様粒子市場規模：用途別分析（ワクチン、治療、バイオイメージング、その他） - 世界のウイルス様粒子市場規模予測（2018年-2029年） - ウイルス様粒子の平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - ウイルス様粒子市場の競争状況およびトレンド ・ウイルス様粒子の地域別市場規模 - 北米のウイルス様粒子市場規模（2018年-2029年） - アメリカのウイルス様粒子市場規模（2018年-2029年） - ヨーロッパのウイルス様粒子市場規模（2018年-2029年） - アジア太平洋のウイルス様粒子市場規模（2018年-2029年） - 中国のウイルス様粒子市場規模（2018年-2029年） - 日本のウイルス様粒子市場規模（2018年-2029年） - 韓国のウイルス様粒子市場規模（2018年-2029年） - インドのウイルス様粒子市場規模（2018年-2029年） - オーストラリアのウイルス様粒子市場規模（2018年-2029年） - 中南米のウイルス様粒子市場規模（2018年-2029年） - 中東・アフリカのウイルス様粒子市場規模（2018年-2029年） ・タイプ別セグメント：大腸菌、酵母、昆虫細胞、その他 - 世界のウイルス様粒子のタイプ別販売量（2018年-2023年） - 世界のウイルス様粒子のタイプ別売上（2018年-2023年） - 世界のウイルス様粒子のタイプ別価格 ・用途別セグメント：ワクチン、治療、バイオイメージング、その他 - 世界のウイルス様粒子の用途別販売量（2018年-2023年） - 世界のウイルス様粒子の用途別売上（2018年-2023年） - 世界のウイルス様粒子の用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 The Native Antigen Company、Creative BioStructure、Creative Biolabs、Leadgene Biomedical、Abcam、ACROBiosystems、Gentarget、VectorBuilder ・産業チェーンと販売チャネルの分析 - ウイルス様粒子産業チェーン分析 - ウイルス様粒子の主要原材料 - ウイルス様粒子の販売チャネル - ウイルス様粒子のディストリビューター - ウイルス様粒子の主要顧客 ・ウイルス様粒子市場ダイナミクス - ウイルス様粒子の業界動向 - ウイルス様粒子市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Virus-like particles (VLPs) are artificial protein structures with a similar overall structure to their corresponding native viruses. They resemble viruses with self-assembly properties but lose original infectious ability due to genome modifications. VLPs are symmetrically built from hundreds of coat proteins, which can be genetically engineered to present a regular arrangement of epitope chains on the desired positions of the outer surface. Compared with monomeric or oligomeric protein carriers, VLPs are able to provide not only a higher density of foreign proteins per particle but also support a distinctive three-dimensional conformation, which is especially important for the presentation of conformational epitopes. Currently, VLPs have been recognized as one of the most promising and extensively studied molecular carriers or nanoparticles, for a variety of applications.
Highlights
The global Virus-like Particle market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Virus-like Particle is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Virus-like Particle is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Virus-like Particle include The Native Antigen Company, Creative BioStructure, Creative Biolabs, Leadgene Biomedical, Abcam, ACROBiosystems, Gentarget and VectorBuilder, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Virus-like Particle, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Virus-like Particle.
The Virus-like Particle market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Virus-like Particle market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Virus-like Particle manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
The Native Antigen Company
Creative BioStructure
Creative Biolabs
Leadgene Biomedical
Abcam
ACROBiosystems
Gentarget
VectorBuilder
Segment by Type
E. coli
Yeast
Insect Cells
Others
Segment by Application
Vaccine
Therapeutics
Bioimaging
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Virus-like Particle manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Virus-like Particle in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Virus-like Particle Market Overview
1.1 Product Overview and Scope of Virus-like Particle
1.2 Virus-like Particle Segment by Type
1.2.1 Global Virus-like Particle Market Value Comparison by Type (2023-2029)
1.2.2 E. coli
1.2.3 Yeast
1.2.4 Insect Cells
1.2.5 Others
1.3 Virus-like Particle Segment by Application
1.3.1 Global Virus-like Particle Market Value by Application: (2023-2029)
1.3.2 Vaccine
1.3.3 Therapeutics
1.3.4 Bioimaging
1.3.5 Others
1.4 Global Virus-like Particle Market Size Estimates and Forecasts
1.4.1 Global Virus-like Particle Revenue 2018-2029
1.4.2 Global Virus-like Particle Sales 2018-2029
1.4.3 Global Virus-like Particle Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Virus-like Particle Market Competition by Manufacturers
2.1 Global Virus-like Particle Sales Market Share by Manufacturers (2018-2023)
2.2 Global Virus-like Particle Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Virus-like Particle Average Price by Manufacturers (2018-2023)
2.4 Global Virus-like Particle Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Virus-like Particle, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Virus-like Particle, Product Type & Application
2.7 Virus-like Particle Market Competitive Situation and Trends
2.7.1 Virus-like Particle Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Virus-like Particle Players Market Share by Revenue
2.7.3 Global Virus-like Particle Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Virus-like Particle Retrospective Market Scenario by Region
3.1 Global Virus-like Particle Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Virus-like Particle Global Virus-like Particle Sales by Region: 2018-2029
3.2.1 Global Virus-like Particle Sales by Region: 2018-2023
3.2.2 Global Virus-like Particle Sales by Region: 2024-2029
3.3 Global Virus-like Particle Global Virus-like Particle Revenue by Region: 2018-2029
3.3.1 Global Virus-like Particle Revenue by Region: 2018-2023
3.3.2 Global Virus-like Particle Revenue by Region: 2024-2029
3.4 North America Virus-like Particle Market Facts & Figures by Country
3.4.1 North America Virus-like Particle Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Virus-like Particle Sales by Country (2018-2029)
3.4.3 North America Virus-like Particle Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Virus-like Particle Market Facts & Figures by Country
3.5.1 Europe Virus-like Particle Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Virus-like Particle Sales by Country (2018-2029)
3.5.3 Europe Virus-like Particle Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Virus-like Particle Market Facts & Figures by Country
3.6.1 Asia Pacific Virus-like Particle Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Virus-like Particle Sales by Country (2018-2029)
3.6.3 Asia Pacific Virus-like Particle Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Virus-like Particle Market Facts & Figures by Country
3.7.1 Latin America Virus-like Particle Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Virus-like Particle Sales by Country (2018-2029)
3.7.3 Latin America Virus-like Particle Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Virus-like Particle Market Facts & Figures by Country
3.8.1 Middle East and Africa Virus-like Particle Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Virus-like Particle Sales by Country (2018-2029)
3.8.3 Middle East and Africa Virus-like Particle Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Virus-like Particle Sales by Type (2018-2029)
4.1.1 Global Virus-like Particle Sales by Type (2018-2023)
4.1.2 Global Virus-like Particle Sales by Type (2024-2029)
4.1.3 Global Virus-like Particle Sales Market Share by Type (2018-2029)
4.2 Global Virus-like Particle Revenue by Type (2018-2029)
4.2.1 Global Virus-like Particle Revenue by Type (2018-2023)
4.2.2 Global Virus-like Particle Revenue by Type (2024-2029)
4.2.3 Global Virus-like Particle Revenue Market Share by Type (2018-2029)
4.3 Global Virus-like Particle Price by Type (2018-2029)
5 Segment by Application
5.1 Global Virus-like Particle Sales by Application (2018-2029)
5.1.1 Global Virus-like Particle Sales by Application (2018-2023)
5.1.2 Global Virus-like Particle Sales by Application (2024-2029)
5.1.3 Global Virus-like Particle Sales Market Share by Application (2018-2029)
5.2 Global Virus-like Particle Revenue by Application (2018-2029)
5.2.1 Global Virus-like Particle Revenue by Application (2018-2023)
5.2.2 Global Virus-like Particle Revenue by Application (2024-2029)
5.2.3 Global Virus-like Particle Revenue Market Share by Application (2018-2029)
5.3 Global Virus-like Particle Price by Application (2018-2029)
6 Key Companies Profiled
6.1 The Native Antigen Company
6.1.1 The Native Antigen Company Corporation Information
6.1.2 The Native Antigen Company Description and Business Overview
6.1.3 The Native Antigen Company Virus-like Particle Sales, Revenue and Gross Margin (2018-2023)
6.1.4 The Native Antigen Company Virus-like Particle Product Portfolio
6.1.5 The Native Antigen Company Recent Developments/Updates
6.2 Creative BioStructure
6.2.1 Creative BioStructure Corporation Information
6.2.2 Creative BioStructure Description and Business Overview
6.2.3 Creative BioStructure Virus-like Particle Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Creative BioStructure Virus-like Particle Product Portfolio
6.2.5 Creative BioStructure Recent Developments/Updates
6.3 Creative Biolabs
6.3.1 Creative Biolabs Corporation Information
6.3.2 Creative Biolabs Description and Business Overview
6.3.3 Creative Biolabs Virus-like Particle Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Creative Biolabs Virus-like Particle Product Portfolio
6.3.5 Creative Biolabs Recent Developments/Updates
6.4 Leadgene Biomedical
6.4.1 Leadgene Biomedical Corporation Information
6.4.2 Leadgene Biomedical Description and Business Overview
6.4.3 Leadgene Biomedical Virus-like Particle Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Leadgene Biomedical Virus-like Particle Product Portfolio
6.4.5 Leadgene Biomedical Recent Developments/Updates
6.5 Abcam
6.5.1 Abcam Corporation Information
6.5.2 Abcam Description and Business Overview
6.5.3 Abcam Virus-like Particle Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Abcam Virus-like Particle Product Portfolio
6.5.5 Abcam Recent Developments/Updates
6.6 ACROBiosystems
6.6.1 ACROBiosystems Corporation Information
6.6.2 ACROBiosystems Description and Business Overview
6.6.3 ACROBiosystems Virus-like Particle Sales, Revenue and Gross Margin (2018-2023)
6.6.4 ACROBiosystems Virus-like Particle Product Portfolio
6.6.5 ACROBiosystems Recent Developments/Updates
6.7 Gentarget
6.6.1 Gentarget Corporation Information
6.6.2 Gentarget Description and Business Overview
6.6.3 Gentarget Virus-like Particle Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Gentarget Virus-like Particle Product Portfolio
6.7.5 Gentarget Recent Developments/Updates
6.8 VectorBuilder
6.8.1 VectorBuilder Corporation Information
6.8.2 VectorBuilder Description and Business Overview
6.8.3 VectorBuilder Virus-like Particle Sales, Revenue and Gross Margin (2018-2023)
6.8.4 VectorBuilder Virus-like Particle Product Portfolio
6.8.5 VectorBuilder Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Virus-like Particle Industry Chain Analysis
7.2 Virus-like Particle Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Virus-like Particle Production Mode & Process
7.4 Virus-like Particle Sales and Marketing
7.4.1 Virus-like Particle Sales Channels
7.4.2 Virus-like Particle Distributors
7.5 Virus-like Particle Customers
8 Virus-like Particle Market Dynamics
8.1 Virus-like Particle Industry Trends
8.2 Virus-like Particle Market Drivers
8.3 Virus-like Particle Market Challenges
8.4 Virus-like Particle Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer